Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 17:17:12 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

BioInvent Q4 2022 - Focusing on Subcutaneous BI-1206

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

BioInvent Q4 2022 - Focusing on Subcutaneous BI-1206

2023-02-23 07:50:00

Redeye comments on BioInvent's Q4 report. The most significant development in the period is the initiation of a phase I study with a new subcutaneous version of the main candidate BI-1206, which should be free of some of the side effects of the intravenous version.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/